The observation of HER2 (ERBB2) amplification in one tumor can have major impact on treatment strategies in one patient, and for the patient #9, after 1 cycle of lapatinib, the patient was switched to palliative care, due to disease progression. Here, ERBB2 is linked to neoplasm.